Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

European network established to improve infectious disease response

Published

on

Map of Europe

A pan-European network has been established by iiCON: the Infection Innovation Consortium to help harmonise Europe’s response to infectious disease threats.

iiCON secured funding from COST (European Cooperation in Science and Technology) to establish a pan-European COST Action network with over 70 collaborators from 21 countries and international organisations.

The Pan European One Health Network for Infectious Diseases Detection, Monitoring and Prevention will respond to the growing threat of infectious diseases to develop a coordinated, preventative response. Formally launching in October 2026, the network will connect academics, clinicians, veterinarians, engineers, computer scientists, SMEs, policymakers, and civil society to co-develop equitable, scalable solutions.

The multi-stakeholder group aims to bridge existing gaps to support the discovery, validation, and deployment of tools to detect, monitor and prevent infection threats.

Gaps identified by the network include fragmented surveillance frameworks, poor interoperability of datasets, limited predictive modelling, slow regulatory pathways, and uneven diagnostic capacity across regions. These barriers can limit translation from research to practice.

The network will address these gaps through the development of six interlinked working groups:

  • Frameworks and surveillance protocols’ harmonisation (WG1) 
  • Interoperable data pipelines development (WG2) 
  • AI-driven predictive models and diagnostic tools (WG3) 
  • Capacity building and knowledge dissemination (WG4) 
  • Alignment of innovation with regulatory, ethical, and policy frameworks (WG5) 
  • Equity, diversity, and inclusion in Infectious Disease Innovation (WG6).
Fostering public-private collaboration 

Professor Patryk Kot, head of the Infection Innovation Technology Laboratory, led by iiCON, is leading the initiative. He said: “As the longest-running European framework for coordinating nationally funded research across borders, COST has played an important role in supporting and enabling equitable research and innovation over many decades, with tangible impact across Europe and beyond. We’re delighted to have been successful in securing funding and support for this important One Health initiative and to be part of the COST Action network. 

“By enabling an end-to-end innovation pipeline and fostering public-private collaboration, our network will play a key role in accelerating the translation of research into market-ready tools, strengthening Europe’s resilience and preparedness for infectious disease threats. 

“We look forward to working with our diverse group of collaborators to bridge research and innovation gaps – enhancing efficiency, bolstering innovation, and working collaboratively to standardise the European infection response.” 

Professor Janet Hemingway, iiCON’s Founding Ddirector, said: “Infectious diseases pose an increasingly complex and growing threat to our global communities. It is only by working together, sharing knowledge and standardising systems that we can leverage our shared expertise and synergistic capability to discover and develop solutions to combat this universal challenge. 

“COST Action’s commitment to driving forward knowledge sharing and engagement across borders is deeply aligned with iiCON’s focus on collaborative innovation and we look forward to leading this important network – deepening links and enabling impactful partnership working to combat our shared infection threat.”

The post European network established to improve infectious disease response appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read